➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
McKinsey
Harvard Business School
Baxter
Mallinckrodt

Last Updated: September 23, 2020

DrugPatentWatch Database Preview

DEMSER Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Demser patents expire, and when can generic versions of Demser launch?

Demser is a drug marketed by Bausch and is included in one NDA.

The generic ingredient in DEMSER is metyrosine. There are two drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the metyrosine profile page.

US ANDA Litigation and Generic Entry Outlook for Demser

A generic version of DEMSER was approved as metyrosine by AMNEAL on July 24th, 2020.

  Start Trial

Drug patent expirations by year for DEMSER
Drug Prices for DEMSER

See drug prices for DEMSER

Recent Clinical Trials for DEMSER

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Valeant Pharmaceuticals International, Inc.Phase 2
Vanderbilt University Medical CenterPhase 3
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Phase 2

See all DEMSER clinical trials

Pharmacology for DEMSER

US Patents and Regulatory Information for DEMSER

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch DEMSER metyrosine CAPSULE;ORAL 017871-001 Approved Prior to Jan 1, 1982 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
McKesson
Express Scripts
Colorcon
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.